Toggle light / dark theme

The Top 10 Companies Working to Increase Longevity

The core of what we do at Nanalyze is to tell our readers all they need to know about investing in emerging technologies. Sometimes that story is much, much bigger, and what we’re really talking about is investing in emerging industries. NewSpace is one example, launching about 15 years ago with the emergence of companies like SpaceX and Virgin Galactic. It’s probably only within the last five years that the NewSpace industry has achieved real liftoff, with dozens of startups doing everything from offering launch services to building satellites to developing business analytics from space-based imagery. While we may one day end up living on Mars, we’re more interested in living a long and fruitful life right here on Mother Earth, despite the specter of cancer and dementia. An entire industry is coalescing around human longevity, promising to beat these age-related diseases and extend our lives to biblical proportions.

We’ve been covering the topic of life extension for more than five years, beginning with a profile on an anti-aging company called Human Longevity Inc, whose founders include billionaire serial entrepreneur Peter Diamandis and J. Craig Venter, a leading genomics expert. More recently, we introduced you to nine companies developing products in regenerative medicine, a broad category that refers to restoring the structure and function of damaged tissues or organs. We also tackled the more controversial topic of young blood transfusions earlier this year, as well as covered the 2019 IPO of Precision BioSciences (DTIL), a gene-editing company that wants to fight disease and re-engineer food.

Alzheimer’s Gene Therapy Human Study Seeks Volunteers

Integrated Health Systems, in partnership with Maximum Life Foundation, is funding a trial to rejuvenate microglial cells using telomerase gene therapy. This trial is currently looking for ten patients with mild to moderate Alzheimer’s Disease. At this time five of the positions have been filled. The trial will be conducted in MONTEREY, Mexico. Treatment is …“Alzheimer’s Gene Therapy Human Study Seeks Volunteers”

How to Reverse Aging and Live Longer with David Sinclair PhD

💯💯Subscribe for videos on becoming superhuman: https://goo.gl/TSDCuv

Timestamps:

- What Causes Aging and Why It Happens 03:00.
- How to Slow Down the Aging Process 08:57.
- Why Do Sirtuin Genes Promote Longevity 11:50.
- Xenohormesis and Resveratrol 13:55
- What is NAD and How It Affects Aging 18:55.
- Different Types of NAD Boosters 20:46
- Signs of Aging 25:00
- How Dr Sinclair Exercises 29:25
- Metformin, mTOR, and Insulin 34:00
- What’s the Upper Limit for Human Lifespan 39:58.
- What Area of Research Is Most Promising 43:58.

David Sinclair Lifespan Book: https://amzn.to/2nb1dds

Use Code MZFALL2019 for a 25% Discount for Bioptimizers Masszymes Digestive Enzymes: https://bit.ly/30PYUud

Podcast About Longevity Pathways: https://www.youtube.com/watch?v=4mDPEoyKQSg

In-Silico Clinical Trials — Virtual Bodies For Real Drugs — Dr. William Pruett — University of Mississippi Medical Center — ideaXme — Ira Pastor

An Interview with Dr. Ronald Kohanski

It was a pleasure speaking to Dr. Ronald Kohanski at the 2019 Ending Age-Related Diseases conference. Dr. Kohanski joined the field of aging research in 2005 as a Program Officer for the Division of Aging Biology at the National Institute on Aging. He moved on to become its Deputy Director in 2007 and has held the position ever since. Within aging research, he has focused his efforts on the areas of stem cell and cardiovascular biology.

Besides his work at the NIA, Ronald Kohanski is a co-founder and co-leader of the trans-NIH Geroscience Interest Group (GSIG) with which he has organized several summits to discuss and disseminate the group’s focus. The GSIG directs its attention toward aging as the major risk factor for most chronic age-related diseases, and Dr. Kohanski actively encourages researchers to expand studies beyond laboratory animals. He underwrites the importance of addressing the basic biology of aging explicitly in human and non-laboratory animal populations. He believes that age should be considered a fundamental parameter in research that uses animal models of chronic disease.

Dr. Kohanski was trained in the field of biochemistry. He received his PhD from the University of Chicago in 1981, after which he conducted a postdoctoral fellowship with M. Daniel Lane at the Johns Hopkins University School of Medicine. He held a faculty position at the Mount Sinai School of Medicine for 17 years before returning to Johns Hopkins as a faculty member and researcher in the areas of enzymology and developmental biology of the insulin receptor.

/* */